Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Irhythm Technologies ( (IRTC) ) has shared an update.
On July 7, 2025, iRhythm Technologies announced the retirement of long-serving board members Mark Rubash and Ralph Snyderman, M.D., and the appointment of Karen McGinnis and Kevin O’Boyle to the board of directors. Rubash and Snyderman played key roles in the company’s growth and digital health innovation, while McGinnis and O’Boyle bring extensive financial and strategic expertise to support iRhythm’s next phase of growth.
The most recent analyst rating on (IRTC) stock is a Hold with a $78.00 price target. To see the full list of analyst forecasts on Irhythm Technologies stock, see the IRTC Stock Forecast page.
Spark’s Take on IRTC Stock
According to Spark, TipRanks’ AI Analyst, IRTC is a Neutral.
Irhythm Technologies exhibits strong revenue growth and positive cash flow trends, bolstered by a positive technical outlook. However, high leverage, continued losses, and valuation challenges weigh on the overall score. Earnings call insights are encouraging but highlight potential risks.
To see Spark’s full report on IRTC stock, click here.
More about Irhythm Technologies
iRhythm Technologies is a leading digital health care company that develops solutions to detect, predict, and prevent disease. The company combines wearable biosensors, cloud-based data analytics, and proprietary algorithms to transform data from heartbeats into clinically actionable information, focusing on improving patient care.
Average Trading Volume: 497,145
Technical Sentiment Signal: Buy
Current Market Cap: $4.55B
Find detailed analytics on IRTC stock on TipRanks’ Stock Analysis page.